Lupus is a challenge, with doctors and patients facing an ongoing battle to manage this chronic, life-threatening condition. So, to understand it better we recently explored lupus management in a global survey of more than 500 specialist lupus doctors (mainly rheumatologists) and patients.
By asking our consumers what matters to them, we can keep innovating and evolving our products. Importantly, this is not just about using our science to improve the products themselves – but also how the product is delivered.
With vaccines widely available for many of the most common childhood illnesses, like measles and mumps, many people think that the golden age of vaccine development has passed. Our head of Vaccines R&D, Dr Emmanuel Hanon, thinks they’re wrong.
Almost half a century ago, the world entered an apparent golden era of drug discovery. Driven by a rapidly advancing understanding of biological processes in the body and medicinal chemistry, a generation of game-changing new medicines emerged.
We continuously strive for new opportunities to evolve our understanding of COPD that will help us meet individual patient needs.
Since 2014, we’ve been transforming the way we do research using digital technologies and channels to improve the efficiency of our research, and to improve patient care.
Picture a world where people routinely die from minor infections, where invasive surgery like organ transplants can’t be performed because it’s too risky, and where hospital wards are breeding grounds for disease.
Scientists are discovering just how important microbes are in maintaining our respiratory health and immunity
As science evolves we are learning that the immune system does so much more than protect us from an outside attack.
Bioelectronic medicine is a vision far from today’s medical practice. But we believe that one day, tiny devices, smaller than grains of rice, could be used to restore health in a range of chronic diseases centred on organs and biological functions.
Martin Andrews leads our Rare Diseases Unit to help advance the treatment of patients affected by rare diseases. He was appointed Senior Vice President, GSK Rare Diseases in November 2013.
Since the structure of DNA was discovered by James Watson and Francis Crick in 1953, significant advances have been made in our understanding of diseases caused by faulty genes.
That’s why we’re working with a range of partners, including the McLaren Technology Group and Medidata, to find new ways to use biosensors and mobile health platforms to improve patient care.
In the words of the author and biochemist Isaac Asimov, "The most exciting phrase to hear in science, the one that heralds new discoveries, is not 'Eureka!', but 'That's funny…'"
The number of people living with dementia worldwide is set to treble by 2050 to 135 million, according to the World Health Organization.
Find out how we are breeding 2,000 mosquitoes every week in the search for anti-malarial medicines.
What if instead of trying to see off the bugs, we harnessed them and made them work for us, instead of against us?
We have a long-standing commitment to data transparency.
"The biggest surprise for me was the openness,” says Thulasi Warrier. “I thought I would be put in a cubicle and not encouraged to speak.”
Find out how our scientists have adapted an ingredient from a GSK mouthwash into a potentially life-saving gel for newborns in developing countries.